IMPLANON (etonogestrel) by Merck & Co. is ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium. First approved in 2006.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
IMPLANON is a subdermal contraceptive implant containing etonogestrel, a synthetic progestin approved in 2006. It prevents pregnancy through suppression of the luteinizing hormone surge, increased cervical mucus viscosity, and endometrial alterations. The single-rod implant provides continuous contraception for three years and represents a long-acting reversible contraception (LARC) option.
Product is at peak commercialization with sustained market presence; brand teams maintain stable headcount focused on market defense against competitive pressure (competitive pressure score: 8/10).
ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Barriers to Referring Adolescent Women for Etonogestrel Implant.
Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring
Etonogestrel Implant as Emergency Contraception
Antepartum Etonogestrel Contraceptive Implant Insertion at Term
Worked on IMPLANON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moMerck & Co. is hiring 1 role related to this product
LOE in ~4 years — strategic planning for patent cliff underway
Working on IMPLANON offers stability and deep contraceptive market expertise but limited growth momentum given peak lifecycle stage and approaching LOE. Roles focus on defending market share against competitive pressure and managing the transition to generic competition.